Shionogi & Co., Ltd. (TYO:4507)
Japan
· Delayed Price · Currency is JPY | Market Cap | 2.26T |
| Revenue (ttm) | 437.26B |
| Net Income (ttm) | 170.84B |
| Shares Out | 850.98M |
| EPS (ttm) | 200.75 |
| PE Ratio | 13.21 |
| Forward PE | 11.94 |
| Dividend | 66.00 (2.45%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 2,024,600 |
| Average Volume | 2,430,140 |
| Open | 2,650.50 |
| Previous Close | 2,694.50 |
| Day's Range | 2,627.00 - 2,661.50 |
| 52-Week Range | 2,100.00 - 2,775.00 |
| Beta | -0.09 |
| RSI | 50.76 |
| Earnings Date | Jan 30, 2026 |
About Shionogi &
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Osaka, Japan. [Read more]
Financial Performance
In 2024, Shionogi &'s revenue was 438.27 billion, an increase of 0.73% compared to the previous year's 435.08 billion. Earnings were 170.44 billion, an increase of 5.19%.
Financial StatementsNews
Shionogi & Co., Ltd. 2025 Q1 - Results - Earnings Call Presentation
Shionogi & Co., Ltd. (SGIOY) Q1 2025 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2025 Earnings Conference Call July 28, 2025 3:30 AM ET Company Participants John A.
Shionogi & Co. reports Q1 results
Shionogi & Co. GAAP EPS of ¥200.29, revenue of ¥438.27B
Shionogi to buy Japan Tobacco’s Torii Pharma in a deal worth over $1B
Shionogi and Jordan's Guardian Angels Announce First-Ever Human Drug Study for Jordan's Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder
Large-Scale Research and Grassroots Patient Advocacy Collaborations Led to Historic Milestone for Rare Disease Community Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshir...
Shionogi & Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation
Shionogi targets JPY550B revenue through QOL focus and global expansion
Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q3 2024 Earnings Conference Call January 31, 2025 3:30 AM ETCompany ParticipantsYoshimasa Kyokawa - VP, Corporate...
Shionogi & Co. reports 9M results
Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q2 2024 Earnings Call Transcript October 29, 2024 2:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Isao Teshirogi - Chair...
Antibiotics, an important but tricky business, says Shionogi CEO [Advocacy Lab Content]
Producing antibiotics remains imperative but production is hindered by an unattractive business model, says Shionogi CEO. Pull incentives are needed to ensure safe, global supplies of vital drugs.
Shionogi & Co., Ltd. (SGIOY) Q1 2024 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOY) Q1 2024 Earnings Conference Call July 29, 2024 4:00 AM ET Company Participants Yoshimasa Kyokawa - Vice President, Corporate Communications Masako Kudou - Vice Presi...
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) and Maze Therapeutic...
Shionogi & Co., Ltd. (SGIOF) Q2 2023 Earnings Conference Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOF) Q2 2023 Earnings Conference Call October 31, 2023 9:30 PM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications Isao Teshirogi - Representative Di...
Shionogi & Co., Ltd. (SGIOF) Q1 2023 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOF) Q1 2023 Earnings Conference Call July 31, 2023 5:15 AM ET Company Participants Yoshimasa Kyokawa - VP, Corporate Communications John Keller - Senior Executive Office...
Shionogi: Likely The Last Viable COVID Play
Xocova is an approved-in-Japan COVID antiviral. Other COVID investments are causing valuations to fall as their opportunities subside.
Shionogi & Co., Ltd. (SGIOF) Q3 2022 Earnings Call Transcript
Shionogi & Co., Ltd. (OTCPK:SGIOF) Q3 2022 Earnings Conference Call January 30, 2023 1:00 AM ET Company Participants Yoshimasa Kyokawa - Investor Relations Masako Kudou - Vice President, Finance and A...